I
IM THERAPEUTICS
IM Therapeutics is developing personalized immuno-therapeutic drugs for autoimmune diseases based on the genetic risk attributed by human leukocyte antigen (HLA) genes. Their lead candidate drug is an oral drug that starves the autoimmune process in type 1 diabetes (T1D) by blocking DQ8 on specific immune cells. Their goal is to preserve pancreatic beta cell function and maintain normal insulin production in at-risk and early-stage patients with type 1 diabetes. They are leveraging Their HLA platform to expand their pipeline beyond T1D, to include drug development for Celiac disease (gluten sensitivity) as well as potential additional autoimmune diseases.
Country/Area ：United States
Company Email ：info@imtherapeutics.com
Industry ：Business ServicesBusiness Services General
Company address ：STEVE ORNDORFF 11001 W 120TH AVE STE 400 UNITED STATES
Company website ：*****
Company phone ：(303) 544-2104
Established ：2015
Company Revenue ：$3,096,000
Number of employees ：1-10
SIC Code ：28283
NAICS Code ：32325
Company News
IM Therapeutics Reports Positive Results in Safety, Tolerability and Mechanism of Action of Phase 1b Trial of Lead Drug IMT-002 in Type 1 Diabetes
Jul 21, 2021
WOBURN, Mass.--(BUSINESS WIRE)-- #imtherapeutics--IM Therapeutics announced positive results in a Phase 1b study of IMT-002 in patients with type 1 diabetes (T1D).
Jul 21, 2021
IM Therapeutics Co-Founder and CMO Peter Gottlieb, M.D, to Present Advances in Genetically Targeted Therapies for Type 1 Diabetes at the 2021 ADA Scientific SessionsJun 24, 2021
WOBURN, Mass.--(BUSINESS WIRE)-- #Autoimmunedisease--IM Therapeutics, Inc. announced today that Peter Gottlieb, M.D., Co-founder and Chief Medical Officer, will present at the American Diabetes Association (ADA) 81st Scientific Sessions, held June 25-29, 2021. IM Therapeutics is a clinical-stage company developing novel, first-in-class therapies targeting human leukocyte antigens (HLAs) to treat autoimmune diseases. Dr. Gottlieb’s talk, entitled “Genetically Selected Patients for Targeted Immune
Jun 24, 2021IM Therapeutics Expands Management Team with David Alleva, Ph.D. as VP, ImmunologyApr 6, 2021
WOBURN, Mass.--(BUSINESS WIRE)-- #Autoimmunedisease--IM Therapeutics, Inc., a clinical-stage company developing novel, first-in-class therapies targeting human leukocyte antigens (HLAs) to treat autoimmune diseases, announced today that David Alleva, Ph.D., has joined its management team as Vice President, Immunology. Dr. Alleva is an immunologist with deep experience in R&D in autoimmunity and infectious disease spanning 22 years and across early-stage biotech, foundations, and clinical-stage b
Apr 6, 2021IM Therapeutics Announces Appointment of Jonathan Rigby to Board of DirectorsJan 27, 2021
WOBURN, Mass.--(BUSINESS WIRE)-- #HLAtarget--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known
Jan 27, 2021IM Therapeutics Launches Phase 1b Trial of Lead Drug IMT-002 in Autoimmunity; Announces Positive Safety Data of Phase 1a StudyOct 29, 2020
WOBURN, Mass.--(BUSINESS WIRE)-- #Autoimmunedisease--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a leading innovator in the field of precision medicine for autoimmune diseases, today announced it has launched a Phase 1b study as a multiple ascending dose (MAD) trial. The study is in patients who have type 1 diabetes (T1D), an as yet incurable autoimmune disorder that affects nearly 1.6 million Americans, and who also have a specific genetic trait known as HLA-DQ8, present in about 60
Oct 29, 2020Web Summary
Q1: What is the address of IM Therapeutics' headquarters?
A1: IM Therapeutics has two locations: 299 Washington St. Suite A, Woburn, MA 01801 (Massachusetts) and 12635 E. Montview Blvd. Suite 128, Aurora, CO 80045 (Colorado).
Q2: What is the therapeutic focus of IM Therapeutics?
A2: IM Therapeutics is building an HLA-directed platform for new therapies, focusing on targeting the root cause of autoimmunity with first-of-its-kind targeted drug design and a patient-centered approach.
Q3: In which diseases does IM Therapeutics aim to develop targeted therapies?
A3: The company aims to develop targeted therapies for autoimmune diseases such as Type 1 Diabetes, Celiac Disease, and other HLA-related autoimmune indications.
Q4: What is the unique approach of IM Therapeutics' drug development platform?
A4: IM Therapeutics' platform employs a novel approach to balance the affinity to HLA binding site(s) to achieve blockade versus protecting inherent immunity against pathogens conferred by the HLA proteins.
Q5: Who are the founders of IM Therapeutics?
A5: IM Therapeutics was founded by renowned physician scientists Drs. Aaron Michels and Peter Gottlieb, based on the ground-breaking work led by the late Professor George Eisenbarth.
Q6: What is the significance of HLA variants in autoimmune diseases according to IM Therapeutics?
A6: According to IM Therapeutics, HLA variants known to confer high disease risk are targeted with therapeutic design directed at these proteins, which are believed to be involved in the trigger of autoimmune responses.
Q7: How does IM Therapeutics' platform differ from existing treatments for autoimmune diseases?
A7: IM Therapeutics' platform is the first to target the root cause of autoimmunity with therapeutic design directed at HLA variants known to confer high disease risk, offering a novel paradigm in drug development.
Q8: What is the contact information for IM Therapeutics?
A8: The contact information for IM Therapeutics includes phone number +1 617.356.8170 and email address info@IMTherapeutics.com, with two locations in Massachusetts and Colorado.
A1: IM Therapeutics has two locations: 299 Washington St. Suite A, Woburn, MA 01801 (Massachusetts) and 12635 E. Montview Blvd. Suite 128, Aurora, CO 80045 (Colorado).
Q2: What is the therapeutic focus of IM Therapeutics?
A2: IM Therapeutics is building an HLA-directed platform for new therapies, focusing on targeting the root cause of autoimmunity with first-of-its-kind targeted drug design and a patient-centered approach.
Q3: In which diseases does IM Therapeutics aim to develop targeted therapies?
A3: The company aims to develop targeted therapies for autoimmune diseases such as Type 1 Diabetes, Celiac Disease, and other HLA-related autoimmune indications.
Q4: What is the unique approach of IM Therapeutics' drug development platform?
A4: IM Therapeutics' platform employs a novel approach to balance the affinity to HLA binding site(s) to achieve blockade versus protecting inherent immunity against pathogens conferred by the HLA proteins.
Q5: Who are the founders of IM Therapeutics?
A5: IM Therapeutics was founded by renowned physician scientists Drs. Aaron Michels and Peter Gottlieb, based on the ground-breaking work led by the late Professor George Eisenbarth.
Q6: What is the significance of HLA variants in autoimmune diseases according to IM Therapeutics?
A6: According to IM Therapeutics, HLA variants known to confer high disease risk are targeted with therapeutic design directed at these proteins, which are believed to be involved in the trigger of autoimmune responses.
Q7: How does IM Therapeutics' platform differ from existing treatments for autoimmune diseases?
A7: IM Therapeutics' platform is the first to target the root cause of autoimmunity with therapeutic design directed at HLA variants known to confer high disease risk, offering a novel paradigm in drug development.
Q8: What is the contact information for IM Therapeutics?
A8: The contact information for IM Therapeutics includes phone number +1 617.356.8170 and email address info@IMTherapeutics.com, with two locations in Massachusetts and Colorado.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
